Request Appointment
12902 Usf Magnolia DrTampa, FL 33612
Overview of Dr. Gray
Dr. Jhanelle Gray is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. She received her medical degree from Weill Cornell Medicine and has been in practice 25 years. Dr. Gray accepts several types of health insurance, listed below. She is one of 200 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. She has more than 100 publications and over 500 citings.
Education & Training
University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General HospitalFellowship, Hematology and Medical Oncology, 2004 - 2007
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2001 - 2004
Weill Cornell MedicineClass of 2001
Certifications & Licensure
FL State Medical License 2004 - 2027
NY State Medical License 2003 - 2005
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification PathNet, Cerner Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification PowerChart (Clinical), Cerner Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification HealtheLife and PowerChart, Cerner Corporation, 2014, 2016-2017
Clinical Trials
- Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers Start of enrollment: 2008 Nov 01
- Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer Start of enrollment: 2012 Mar 26
- Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer Start of enrollment: 2013 Sep 09
Publications & Presentations
PubMed
- First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study.Jhanelle E Gray, Joel W Neal, Jyoti D Patel, Stephen V Liu, Rémi Veillon
Clinical Cancer Research. 2026-04-10 - Relationship between PD-L1 Expression and Outcomes of Salvage Treatment Following Durvalumab Consolidation.Tawee Tanvetyanon, Dung-Tsa Chen, Jhanelle E Gray
Clinical Lung Cancer. 2026-04-01 - Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study.Eziafa I Oduah, Tian Zhang, Sin-Ho Jung, Thomas E Stinchcombe, Neal Ready
Future Oncology. 2026-04-01
Journal Articles
- Overall Survival with Durvalumab After Chemoradiotherapy in Stage III NSCLCDavid R Spigel, Davey Daniel, Jhanelle E Gray, Augusto Villegas, Tarek Mekhail, Alberto Chiappori, The New England Journal of Medicine
Press Mentions
“Another Negative Study”: Phase 3 Failure for Lung Cancer ComboApril 1st, 2026- Much Ado About Nothing? Time of Day May Not Matter for Immunotherapy in Lung CancerMarch 31st, 2026
- These Women Were Diagnosed with Lung Cancer. They Weren't Eligible for ScreeningNovember 20th, 2025
Professional Memberships
- Member
Insurance Accepted
- Aetna HMO
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPOCoventry Florida - Employer Group PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
